Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
Add more filters











Publication year range
1.
Eur J Med Chem ; 278: 116796, 2024 Nov 15.
Article in English | MEDLINE | ID: mdl-39241483

ABSTRACT

To achieve malaria eradication, new preventative agents that act differently to front-line treatment drugs are needed. To identify potential chemoprevention starting points we screened a sub-set of the CSIRO Australia Compound Collection for compounds with slow-action in vitro activity against Plasmodium falciparum. This work identified N,N-dialkyl-5-alkylsulfonyl-1,3,4-oxadiazol-2-amines as a new antiplasmodial chemotype (e.g., 1 96 h IC50 550 nM; 3 96 h IC50 160 nM) with a different action to delayed-death slow-action drugs. A series of analogues were synthesized from thiotetrazoles and carbomoyl derivatives using Huisgen 1,3,4-oxadiazole synthesis followed by oxidation of the resultant thioethers to target sulfones. Structure activity relationship analysis of analogues identified compounds with potent and selective in vitro activity against drug-sensitive and multi-drug resistant Plasmodium parasites (e.g., 31 and 32 96 h IC50 <40 nM; SI > 2500). Subsequent studies in mice with compound 1, which had the best microsomal stability of the compounds assessed (T1/2 >255 min), demonstrated rapid clearance and poor oral in vivo efficacy in a P. berghei murine malaria model. These data indicate that while N,N-dialkyl-5-alkylsulfonyl-1,3,4-oxadiazol-2-amines are a novel class of slow-acting antiplasmodial agents, the further development of this chemotype for malaria chemoprophylaxis will require pharmacokinetic profile improvements.


Subject(s)
Antimalarials , Oxadiazoles , Plasmodium falciparum , Oxadiazoles/chemistry , Oxadiazoles/pharmacology , Oxadiazoles/chemical synthesis , Plasmodium falciparum/drug effects , Antimalarials/pharmacology , Antimalarials/chemistry , Antimalarials/chemical synthesis , Animals , Structure-Activity Relationship , Mice , Parasitic Sensitivity Tests , Molecular Structure , Dose-Response Relationship, Drug , Drug Discovery , Humans , Malaria, Falciparum/drug therapy
2.
Article in English | MEDLINE | ID: mdl-37776606

ABSTRACT

Giardia duodenalis is the causative agent of the neglected diarrhoeal disease giardiasis. While often self-limiting, giardiasis is ubiquitous and impacts hundreds of millions of people annually. It is also a common gastro-intestinal disease of domestic pets, wildlife, and livestock animals. However, despite this impact, there is no vaccine for Giardia currently available. In addition, treatment relies on chemotherapies that are associated with increasing failure rates. To identify new treatment options for giardiasis we recently screened the Compounds Australia Scaffold Library for new chemotypes with selective anti-Giardia activity, identifying three compounds with sub-µM activity and promising selectivity. Here we extended these studies by examining the anti-Giardia activity of series CL9569 compounds. This compound series was of interest given the promising activity (IC50 1.2 µM) and selectivity demonstrated by representative compound, SN00798525 (1). Data from this work has identified an additional three thieno [3,2-b]pyrrole 5-carboxamides with anti-Giardia activity, including 2 which displayed potent cytocidal (IC50 ≤ 10 nM) and selective activity against multiple Giardia strains, including representatives from both human-infecting assemblages and metronidazole resistant parasites. Preclinical studies in mice also demonstrated that 2 is well-tolerated, does not impact the normal gut microbiota and can reduce Giardia parasite burden in these animals.


Subject(s)
Giardia lamblia , Giardiasis , Parasites , Humans , Animals , Mice , Giardiasis/drug therapy , Giardiasis/veterinary , Giardiasis/parasitology , Giardia , Metronidazole/therapeutic use , Feces/parasitology
3.
Biomedicines ; 10(12)2022 Dec 08.
Article in English | MEDLINE | ID: mdl-36551938

ABSTRACT

On an annual basis the flagellate protozoan, Giardia duodenalis, is responsible for an estimated one billion human infections of which approximately two hundred million cause disease. However, the treatment of Giardia infections is reliant on a small group of chemotherapeutic classes that have a broad spectrum of antimicrobial activity and increasing treatment failure rates. To improve this situation, we need new drugs. In this study we screened the Compounds Australia Scaffolds Library for compounds with potent and selective activity against these parasites. Unlike previous drug discovery efforts that have focused on drug repurposing, this library is comprised of commercially available synthetic compounds arranged into lead-like scaffolds to facilitate structure activity relationship assessments and de novo drug discovery. A screen of 2451 compounds in this library identified 40 hits (>50% inhibitory activity at 10 µM, over 48 h). Secondary testing identified three compounds with IC50 values <1 µM and >50-fold selectivity for parasites over mammalian cells and a hit series, CL9406, comprising compounds with potent (lowest IC50 180 nM) and selective activity for Giardia parasites. The most promising compound in this series, SN00797640, displayed selective activity against assemblage A, B, and metronidazole resistant parasites which was parasiticidal (minimum lethal concentration 625 nM) and synergistic with albendazole. SN00797640 was well-tolerated when administered to mice at doses of 50 mg/kg daily for three days paving the way for pre-clinical in vivo activity assessment.

4.
ACS Infect Dis ; 8(1): 106-117, 2022 01 14.
Article in English | MEDLINE | ID: mdl-34985259

ABSTRACT

Malaria, caused by Plasmodium parasites, results in >400,000 deaths annually. There is no effective vaccine, and new drugs with novel modes of action are needed because of increasing parasite resistance to current antimalarials. Histone deacetylases (HDACs) are epigenetic regulatory enzymes that catalyze post-translational protein deacetylation and are promising malaria drug targets. Here, we describe quantitative structure-activity relationship models to predict the antiplasmodial activity of hydroxamate-based HDAC inhibitors. The models incorporate P. falciparum in vitro activity data for 385 compounds containing a hydroxamic acid and were subject to internal and external validation. When used to screen 22 new hydroxamate-based HDAC inhibitors for antiplasmodial activity, model A7 (external accuracy 91%) identified three hits that were subsequently verified as having potent in vitro activity against P. falciparum parasites (IC50 = 6, 71, and 84 nM), with 8 to 51-fold selectivity for P. falciparum versus human cells.


Subject(s)
Malaria , Parasites , Animals , Histone Deacetylase Inhibitors/pharmacology , Humans , Hydroxamic Acids/pharmacology , Plasmodium falciparum , Quantitative Structure-Activity Relationship
5.
Int J Parasitol Drugs Drug Resist ; 14: 249-256, 2020 12.
Article in English | MEDLINE | ID: mdl-33279862

ABSTRACT

The prevention and treatment of malaria requires a multi-pronged approach, including the development of drugs that have novel modes of action. Histone deacetylases (HDACs), enzymes involved in post-translational protein modification, are potential new drug targets for malaria. However, the lack of recombinant P. falciparum HDACs and suitable activity assays, has made the investigation of compounds designed to target these enzymes challenging. Current approaches are indirect and include assessing total deacetylase activity and protein hyperacetylation via Western blot. These approaches either do not allow differential compound effects to be determined or suffer from low throughput. Here we investigated dot blot and ELISA methods as new, higher throughput assays to detect histone lysine acetylation changes in P. falciparum parasites. As the ELISA method was found to be superior to the dot blot assay using the control HDAC inhibitor vorinostat, it was used to evaluate the histone H3 and H4 lysine acetylation changes mediated by a panel of six HDAC inhibitors that were shown to inhibit P. falciparum deacetylase activity. Vorinostat, panobinostat, trichostatin A, romidepsin and entinostat all caused an ~3-fold increase in histone H4 acetylation using a tetra-acetyl lysine antibody. Tubastatin A, the only human HDAC6-specific inhibitor tested, also caused H4 hyperacetylation, but to a lesser extent than the other compounds. Further investigation revealed that all compounds, except tubastatin A, caused hyperacetylation of the individual N-terminal H4 lysines 5, 8, 12 and 16. These data indicate that tubastatin A impacts P. falciparum H4 acetylation differently to the other HDAC inhibitors tested. In contrast, all compounds caused hyperacetylation of histone H3. In summary, the ELISA developed in this study provides a higher throughput approach to assessing differential effects of antiplasmodial compounds on histone acetylation levels and is therefore a useful new tool in the investigation of HDAC inhibitors for malaria.


Subject(s)
Histone Deacetylase Inhibitors , Lysine , Acetylation , Enzyme-Linked Immunosorbent Assay , Histones/metabolism , Humans , Protein Processing, Post-Translational
6.
mBio ; 11(6)2020 12 08.
Article in English | MEDLINE | ID: mdl-33293381

ABSTRACT

Plasmodium parasites rely heavily on glycolysis for ATP production and for precursors for essential anabolic pathways, such as the methylerythritol phosphate (MEP) pathway. Here, we show that mutations in the Plasmodium falciparum glycolytic enzyme, phosphofructokinase (PfPFK9), are associated with in vitro resistance to a primary sulfonamide glycoside (PS-3). Flux through the upper glycolysis pathway was significantly reduced in PS-3-resistant parasites, which was associated with reduced ATP levels but increased flux into the pentose phosphate pathway. PS-3 may directly or indirectly target enzymes in these pathways, as PS-3-treated parasites had elevated levels of glycolytic and tricarboxylic acid (TCA) cycle intermediates. PS-3 resistance also led to reduced MEP pathway intermediates, and PS-3-resistant parasites were hypersensitive to the MEP pathway inhibitor, fosmidomycin. Overall, this study suggests that PS-3 disrupts core pathways in central carbon metabolism, which is compensated for by mutations in PfPFK9, highlighting a novel metabolic drug resistance mechanism in P. falciparumIMPORTANCE Malaria, caused by Plasmodium parasites, continues to be a devastating global health issue, causing 405,000 deaths and 228 million cases in 2018. Understanding key metabolic processes in malaria parasites is critical to the development of new drugs to combat this major infectious disease. The Plasmodium glycolytic pathway is essential to the malaria parasite, providing energy for growth and replication and supplying important biomolecules for other essential Plasmodium anabolic pathways. Despite this overreliance on glycolysis, no current drugs target glycolysis, and there is a paucity of information on critical glycolysis targets. Our work addresses this unmet need, providing new mechanistic insights into this key pathway.


Subject(s)
Antimalarials/pharmacology , Glycosides/pharmacology , Phosphofructokinases/metabolism , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Alleles , Antimalarials/chemistry , Dose-Response Relationship, Drug , Drug Resistance , Erythrocytes/metabolism , Erythrocytes/parasitology , Glycolysis , Glycosides/chemistry , Metabolomics/methods , Models, Molecular , Molecular Structure , Parasitic Sensitivity Tests , Phosphofructokinases/genetics , Plasmodium falciparum/genetics , Polymorphism, Single Nucleotide , Protein Conformation , Structure-Activity Relationship
7.
J Med Chem ; 63(22): 13330-13354, 2020 11 25.
Article in English | MEDLINE | ID: mdl-32869995

ABSTRACT

Giardia parasites are ubiquitous protozoans of global importance that impact a wide range of animals including humans. They are the most common enteric pathogen of cats and dogs in developed countries and infect ∼1 billion people worldwide. While Giardia infections can be asymptomatic, they often result in severe and chronic diseases. There is also mounting evidence that they are linked to postinfection disorders. Despite growing evidence of the widespread morbidity associated with Giardia infections, current treatment options are limited to compound classes with broad antimicrobial activity. Frontline anti-Giardia drugs are also associated with increasing drug resistance and treatment failures. To improve the health and well-being of millions, new selective anti-Giardia drugs are needed alongside improved health education initiatives. Here we discuss current treatment options together with recent advances and gaps in drug discovery. We also propose criteria to guide the discovery of new anti-Giardia compounds.


Subject(s)
Antiprotozoal Agents/administration & dosage , Drug Discovery/trends , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/parasitology , Giardia/drug effects , Giardiasis/drug therapy , Animals , Antiprotozoal Agents/chemistry , Benzimidazoles/administration & dosage , Benzimidazoles/chemistry , Drug Delivery Systems/methods , Drug Delivery Systems/trends , Drug Discovery/methods , Drug Therapy, Combination , Giardia/physiology , Giardiasis/physiopathology , Humans , Nitroimidazoles/administration & dosage , Nitroimidazoles/chemistry , Nitroimidazoles/therapeutic use
8.
Article in English | MEDLINE | ID: mdl-32234669

ABSTRACT

Giardia duodenalis, the most prevalent human intestinal parasite causes the disease, giardiasis. On an annual basis G. duodenalis infects ~1 billion people, of which ~280 million develop symptomatic disease. Giardiasis can be severe and chronic, causing malnutrition, stunted growth and poor cognitive development in children. Current treatment options rely on drugs with declining efficacy and side-effects. To improve the health and well-being of millions of people world-wide, new anti-Giardia drugs with different modes of action to currently used drugs are required. The Medicines for Malaria Venture's Pathogen Box, a collection of bio-active compounds specifically chosen to stimulate infectious disease drug discovery, represents an opportunity for the discovery of new anti-Giardia agents. While the anti-Giardia activity of Pathogen Box compounds has been reported, this work failed to identify known anti-Giardia controls within the compound set. It also reported the activity of compounds previously screened and shown to be inactive by others, suggesting data may be inaccurate. Given these concerns the anti-Giardia activity of Pathogen Box compounds was re-assessed in the current study. Data from this work identified thirteen compounds with anti-Giardia IC50 values ≤2 µM. Five of these compounds were reference compounds (marketed drugs with known anti-microbial activity), or analogues of compounds with previously described anti-Giardia activity. However, eight, including MMV676358 and MMV028694, which demonstrated potent sub-µM IC50s against assemblage A, B and metronidazole resistant parasites (0.3 µM and 0.9 µM respectively), may represent new leads for future drug development. Interestingly, only four of these compounds were identified in the previously reported Pathogen Box screen highlighting the importance of assay selection and design when assessing compounds for activity against infectious agents.


Subject(s)
Antiparasitic Agents/isolation & purification , Antiparasitic Agents/pharmacology , Biological Assay/methods , Drug Discovery/methods , Giardia lamblia/drug effects , Giardia/drug effects , Drug Discovery/instrumentation , Giardiasis/drug therapy , Humans , Inhibitory Concentration 50 , Parasitic Sensitivity Tests , Prevalence
9.
Commun Biol ; 2: 166, 2019.
Article in English | MEDLINE | ID: mdl-31069275

ABSTRACT

Atovaquone-proguanil (Malarone®) is used for malaria prophylaxis and treatment. While the cytochrome bc1-inhibitor atovaquone has potent activity, proguanil's action is attributed to its cyclization-metabolite, cycloguanil. Evidence suggests that proguanil has limited intrinsic activity, associated with mitochondrial-function. Here we demonstrate that proguanil, and cyclization-blocked analogue tBuPG, have potent, but slow-acting, in vitro anti-plasmodial activity. Activity is folate-metabolism and isoprenoid biosynthesis-independent. In yeast dihydroorotate dehydrogenase-expressing parasites, proguanil and tBuPG slow-action remains, while bc1-inhibitor activity switches from comparatively fast to slow-acting. Like proguanil, tBuPG has activity against P. berghei liver-stage parasites. Both analogues act synergistically with bc1-inhibitors against blood-stages in vitro, however cycloguanil antagonizes activity. Together, these data suggest that proguanil is a potent slow-acting anti-plasmodial agent, that bc1 is essential to parasite survival independent of dihydroorotate dehydrogenase-activity, that Malarone® is a triple-drug combination that includes antagonistic partners and that a cyclization-blocked proguanil may be a superior combination partner for bc1-inhibitors in vivo.


Subject(s)
Antimalarials/pharmacology , Atovaquone/pharmacology , Enzyme Inhibitors/pharmacology , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Proguanil/analogs & derivatives , Animals , Anopheles , Antimalarials/chemistry , Atovaquone/chemistry , Cyclization/drug effects , Dihydroorotate Dehydrogenase , Dose-Response Relationship, Drug , Drug Combinations , Electron Transport Complex III/antagonists & inhibitors , Electron Transport Complex III/metabolism , Enzyme Inhibitors/chemistry , Erythrocytes/drug effects , Erythrocytes/parasitology , Folic Acid/metabolism , Hep G2 Cells , Humans , Inhibitory Concentration 50 , Liver/drug effects , Liver/parasitology , Oxidoreductases Acting on CH-CH Group Donors/metabolism , Plasmodium berghei/growth & development , Plasmodium berghei/metabolism , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , Proguanil/chemistry , Proguanil/pharmacology , Sporozoites/drug effects , Sporozoites/growth & development , Sporozoites/metabolism , Terpenes/metabolism , Triazines/chemistry , Triazines/pharmacology
10.
Exp Parasitol ; 198: 7-16, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30682336

ABSTRACT

Plasmodium falciparum histone deacetylases (PfHDACs) are an important class of epigenetic regulators that alter protein lysine acetylation, contributing to regulation of gene expression and normal parasite growth and development. PfHDACs are therefore under investigation as drug targets for malaria. Despite this, our understanding of the biological roles of these enzymes is only just beginning to emerge. In higher eukaryotes, HDACs function as part of multi-protein complexes and act on both histone and non-histone substrates. Here, we present a proteomics analysis of PfHDAC1 immunoprecipitates, identifying 26 putative P. falciparum complex proteins in trophozoite-stage asexual intraerythrocytic parasites. The co-migration of two of these (P. falciparum heat shock proteins 70-1 and 90) with PfHDAC1 was validated using Blue Native PAGE combined with Western blot. These data provide a snapshot of possible PfHDAC1 interactions and a starting point for future studies focused on elucidating the broader function of PfHDACs in Plasmodium parasites.


Subject(s)
Histone Deacetylase 1/analysis , Plasmodium falciparum/enzymology , Proteomics , Protozoan Proteins/chemistry , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Histone Deacetylase 1/chemistry , Immunoprecipitation , Mass Spectrometry/methods
11.
Eur J Med Chem ; 161: 277-291, 2019 Jan 01.
Article in English | MEDLINE | ID: mdl-30366254

ABSTRACT

Despite the recent reductions in the global burden of malaria, this disease remains a devastating cause of death in tropical and subtropical regions. As there is no broadly effective vaccine for malaria, prevention and treatment still rely on chemotherapy. Unfortunately, emerging resistance to the gold standard artemisinin combination therapies means that new drugs with novel modes of action are urgently needed. In this context, Plasmodium histone modifying enzymes have emerged as potential drug targets, prompting us to develop and optimize compounds directed against such epigenetic targets. A panel of 51 compounds designed to target different epigenetic enzymes were screened for activity against Plasmodium falciparum parasites. Based on in vitro activity against drug susceptible and drug-resistant P. falciparum lines, selectivity index criterion and favorable pharmacokinetic properties, four compounds, one HDAC inhibitor (1) and three DNMT inhibitors (37, 43 and 45), were selected for preclinical studies in a mouse model of malaria. In vivo data showed that 37, 43 and 45 exhibited oral efficacy in the mouse model of Plasmodium berghei infection. These compounds represent promising starting points for the development of novel antimalarial drugs.


Subject(s)
Antimalarials/pharmacology , Plasmodium berghei/drug effects , Plasmodium falciparum/drug effects , Quinazolines/pharmacology , Animals , Antimalarials/chemical synthesis , Antimalarials/chemistry , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Fibroblasts/microbiology , Humans , Mice , Mice, Inbred BALB C , Molecular Conformation , Parasitic Sensitivity Tests , Plasmodium falciparum/growth & development , Quinazolines/chemical synthesis , Quinazolines/chemistry , Structure-Activity Relationship
12.
Int J Parasitol Drugs Drug Resist ; 8(2): 189-193, 2018 08.
Article in English | MEDLINE | ID: mdl-29631126

ABSTRACT

Bromodomain-containing proteins (BDPs) are involved in the regulation of eukaryotic gene expression. Compounds that bind and/or inhibit BDPs are of interest as tools to better understand epigenetic regulation, and as possible drug leads for different diseases, including malaria. In this study, we assessed the activity of 42 compounds demonstrated or predicted (using virtual screening of a pharmacophore model) to bind/inhibit eukaryotic BDPs for activity against Plasmodium falciparum malaria parasites. In silico docking studies indicated that all compounds are predicted to participate in a typical hydrogen bond interaction with the conserved asparagine (Asn1436) of the P. falciparum histone acetyltransferase (PfGCN5) bromodomain and a conserved water molecule. Only one compound (the dimethylisoxazole SGC-CBP30; a selective inhibitor of CREBBP (CBP) and EP300 bromodomains) is also predicted to have a salt-bridge between the morpholine nitrogen and Glu1389. When tested for in vitro activity against asynchronous asexual stage P. falciparum Dd2 parasites, all compounds displayed 50% growth inhibitory concentrations (IC50) >10 µM. Further testing of the three most potent compounds using synchronous parasites for 72 h showed that SGC-CBP30 was the most active (IC50 3.2 µM). In vitro cytotoxicity assays showed that SGC-CBP30 has ∼7-fold better selectivity for the parasites versus a human cell line (HEK 293). Together these data provide a possible starting point for future investigation of these, or related compounds, as tools to understand epigenetic regulation or as potential new drug leads.


Subject(s)
Life Cycle Stages/drug effects , Nuclear Proteins/antagonists & inhibitors , Nuclear Proteins/pharmacology , Plasmodium falciparum/drug effects , Antimalarials/pharmacology , Benzimidazoles/pharmacology , Cell Survival/drug effects , Computer Simulation , Drug Discovery , HEK293 Cells , Humans , Inhibitory Concentration 50 , Isoxazoles/pharmacology , Molecular Docking Simulation/methods , Structure-Activity Relationship
13.
J Org Chem ; 82(24): 13313-13323, 2017 12 15.
Article in English | MEDLINE | ID: mdl-29124922

ABSTRACT

Three new isocyanoditerpenes (5-7) have been characterized from Australian specimens of the nudibranch Phyllidiella pustulosa. The planar structure and (3R,6S,7R) absolute configuration of pustulosaisonitrile-1 were deduced by spectroscopic analyses at 900 MHz informed by molecular modeling, DFT calculations, and computational NMR chemical shift predictions and by comparison of experimental electronic circular dichroism (ECD) data with TDDFT-ECD calculations for the truncated model compound 8. A catalyst-controlled enantio- and diastereoselective total synthesis of the two most likely diastereomeric candidates for the structure of 5 solidified its (3R,6S,7R,10S,11R,14R) absolute configuration. Three individual enantioselective methods provided stereochemical control at key positions, permitting an unambiguous final structural assignment. Isocyanide 5 and synthetic diastereomers 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 ∼1 µM).


Subject(s)
Antimalarials/chemistry , Plasmodium falciparum/drug effects , Triazines/chemistry , Animals , Antimalarials/pharmacology , Catalysis , Gastropoda/chemistry , Inhibitory Concentration 50 , Molecular Structure , Stereoisomerism
14.
Int J Parasitol Drugs Drug Resist ; 7(1): 83-89, 2017 04.
Article in English | MEDLINE | ID: mdl-28171818

ABSTRACT

Giardia duodenalis is an intestinal parasite that causes giardiasis, a widespread human gastrointestinal disease. Treatment of giardiasis relies on a small arsenal of compounds that can suffer from limitations including side-effects, variable treatment efficacy and parasite drug resistance. Thus new anti-Giardia drug leads are required. The search for new compounds with anti-Giardia activity currently depends on assays that can be labour-intensive, expensive and restricted to measuring activity at a single time-point. Here we describe a new in vitro assay to assess anti-Giardia activity. This image-based assay utilizes the Perkin-Elmer Operetta® and permits automated assessment of parasite growth at multiple time points without cell-staining. Using this new approach, we assessed the "Malaria Box" compound set for anti-Giardia activity. Three compounds with sub-µM activity (IC50 0.6-0.9 µM) were identified as potential starting points for giardiasis drug discovery.


Subject(s)
Antiprotozoal Agents/isolation & purification , Antiprotozoal Agents/pharmacology , Drug Discovery , Giardia lamblia/drug effects , Antiprotozoal Agents/chemistry , Automation , Drug Resistance , Giardia lamblia/growth & development , Image Processing, Computer-Assisted , Life Cycle Stages/drug effects , Parasitic Sensitivity Tests
15.
Int J Parasitol Drugs Drug Resist ; 7(1): 42-50, 2017 04.
Article in English | MEDLINE | ID: mdl-28107750

ABSTRACT

Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic diseases and each requires new innovative treatments. Targeting essential parasite pathways, such as those that regulate gene expression and cell cycle progression, is a key strategy for discovering new drug leads. In this study, four clinically approved anti-cancer drugs (Vorinostat, Belinostat, Panobinostat and Romidepsin) that target histone/lysine deacetylase enzymes were examined for in vitro activity against Plasmodium knowlesi, Schistosoma mansoni, Leishmania amazonensis and L. donovani parasites and two for in vivo activity in a mouse malaria model. All four compounds were potent inhibitors of P. knowlesi malaria parasites (IC50 9-370 nM), with belinostat, panobinostat and vorinostat having 8-45 fold selectivity for the parasite over human neonatal foreskin fibroblast (NFF) or human embryonic kidney (HEK 293) cells, while romidepsin was not selective. Each of the HDAC inhibitor drugs caused hyperacetylation of P. knowlesi histone H4. None of the drugs was active against Leishmania amastigote or promastigote parasites (IC50 > 20 µM) or S. mansoni schistosomula (IC50 > 10 µM), however romidepsin inhibited S. mansoni adult worm parings and egg production (IC50 ∼10 µM). Modest in vivo activity was observed in P. berghei infected mice dosed orally with vorinostat or panobinostat (25 mg/kg twice daily for four days), with a significant reduction in parasitemia observed on days 4-7 and 4-10 after infection (P < 0.05), respectively.


Subject(s)
Histone Deacetylase Inhibitors/pharmacology , Leishmania/drug effects , Plasmodium knowlesi/drug effects , Schistosoma mansoni/drug effects , Acetylation , Administration, Oral , Animals , Depsipeptides/pharmacology , HEK293 Cells , Histone Deacetylase Inhibitors/administration & dosage , Histone Deacetylase Inhibitors/therapeutic use , Histone Deacetylases/metabolism , Histones/metabolism , Humans , Hydroxamic Acids/administration & dosage , Hydroxamic Acids/pharmacology , Hydroxamic Acids/therapeutic use , Indoles/administration & dosage , Indoles/pharmacology , Indoles/therapeutic use , Inhibitory Concentration 50 , Leishmania/growth & development , Life Cycle Stages/drug effects , Malaria/drug therapy , Malaria/parasitology , Mice , Panobinostat , Parasitemia/drug therapy , Plasmodium berghei/drug effects , Plasmodium knowlesi/growth & development , Schistosoma mansoni/growth & development , Sulfonamides/pharmacology , Vorinostat
16.
Exp Parasitol ; 169: 13-21, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27373432

ABSTRACT

Infection with the apicomplexan parasite Plasmodium falciparum is a major cause of morbidity and mortality worldwide. One of the striking features of this parasite is its ability to remodel and decrease the deformability of host red blood cells, a process that contributes to disease. To further understand the virulence of Pf we investigated the biochemistry and function of a putative Pf S33 proline aminopeptidase (PfPAP). Unlike other P. falciparum aminopeptidases, PfPAP contains a predicted protein export element that is non-syntenic with other human infecting Plasmodium species. Characterization of PfPAP demonstrated that it is exported into the host red blood cell and that it is a prolyl aminopeptidase with a preference for N-terminal proline substrates. In addition genetic deletion of this exopeptidase was shown to lead to an increase in the deformability of parasite-infected red cells and in reduced adherence to the endothelial cell receptor CD36 under flow conditions. Our studies suggest that PfPAP plays a role in the rigidification and adhesion of infected red blood cells to endothelial surface receptors, a role that may make this protein a novel target for anti-disease interventions strategies.


Subject(s)
Aminopeptidases/metabolism , Erythrocyte Deformability/physiology , Plasmodium falciparum/enzymology , Amino Acid Sequence , Aminopeptidases/chemistry , Aminopeptidases/genetics , Aminopeptidases/immunology , Antibodies, Protozoan/immunology , Blotting, Northern , Blotting, Western , Cell Adhesion/physiology , Elasticity , Erythrocyte Membrane/genetics , Erythrocyte Membrane/physiology , Erythrocytes/parasitology , Gene Knockout Techniques , Humans , Microscopy, Atomic Force , Microscopy, Electron, Transmission , Microscopy, Fluorescence , Plasmodium falciparum/genetics , RNA, Protozoan/chemistry , Real-Time Polymerase Chain Reaction , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Sequence Alignment , Transfection
17.
Antimicrob Agents Chemother ; 60(7): 4361-3, 2016 07.
Article in English | MEDLINE | ID: mdl-27114276

ABSTRACT

The zoonotic malaria parasite Plasmodium knowlesi has recently been established in continuous in vitro culture. Here, the Plasmodium falciparum [(3)H]hypoxanthine uptake assay was adapted for P. knowlesi and used to determine the sensitivity of this parasite to chloroquine, cycloguanil, and clindamycin. The data demonstrate that P. knowlesi is sensitive to all drugs, with 50% inhibitory concentrations (IC50s) consistent with those obtained with P. falciparum This assay provides a platform to use P. knowlesi in vitro for drug discovery.


Subject(s)
Hypoxanthine/metabolism , Malaria/physiopathology , Plasmodium knowlesi/metabolism , Animals , Antimalarials/pharmacology , Chloroquine/pharmacology , Clindamycin/pharmacology , Inhibitory Concentration 50 , Plasmodium falciparum/drug effects , Plasmodium falciparum/metabolism , Plasmodium falciparum/pathogenicity , Plasmodium knowlesi/drug effects , Proguanil/pharmacology , Triazines/pharmacology
18.
Drug Discov Today ; 21(5): 725-39, 2016 05.
Article in English | MEDLINE | ID: mdl-26784142

ABSTRACT

The treatment of major human parasitic infections is dependent on drugs that are plagued by issues of drug resistance. New chemotherapeutics with novel mechanisms of action (MOA) are desperately needed to combat multi-drug-resistant parasites. Although widespread screening strategies are identifying potential new hits for development against most major human parasitic diseases, in many cases such efforts are hindered by limited MOA data. Although MOA data are not essential for drug development, they can facilitate compound triage and provide a mechanism to combat drug resistance. Here we describe and discuss methods currently used to identify the targets of antiparasitic compounds, which could circumvent this bottleneck and facilitate the development of new antiparasitic drugs.


Subject(s)
Antiparasitic Agents/pharmacology , Drug Discovery , Animals , Humans
19.
Mar Drugs ; 13(9): 5784-95, 2015 Sep 15.
Article in English | MEDLINE | ID: mdl-26389920

ABSTRACT

Six regioisomers associated with the tricyclic core of thiaplakortones A-D have been synthesized. Reaction of 1H-indole-4,7-dione and 1-tosyl-1H-indole-4,7-dione with 2-aminoethanesulfinic acid afforded a regioisomeric series, which was subsequently deprotected and oxidized to yield the tricyclic core scaffolds present in the thiaplakortones. All compounds were fully characterized using NMR and MS data. A single crystal X-ray structure was obtained on one of the N-tosyl derivatives. All compounds were screened for in vitro antiplasmodial activity against chloroquine-sensitive (3D7) and multidrug-resistant (Dd2) Plasmodium falciparum parasite lines. Several analogues displayed potent inhibition of P. falciparum growth (IC50 < 500 nM) but only moderate selectivity for P. falciparum versus human neonatal foreskin fibroblast cells.


Subject(s)
Antimalarials/chemical synthesis , Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Triazines/chemical synthesis , Triazines/pharmacology , Models, Molecular , Molecular Structure , Structure-Activity Relationship
20.
Org Biomol Chem ; 13(5): 1558-70, 2015 Feb 07.
Article in English | MEDLINE | ID: mdl-25490858

ABSTRACT

A series of amide (8­32, 40­45) and urea (33, 34, 36­39) analogues based on the thiaplakortone A natural product scaffold were synthesised and screened for in vitro antimalarial activity against chloroquine-sensitive (3D7) and chloroquine- and mefloquine-resistant (Dd2) Plasmodium falciparum parasite lines. Several analogues displayed potent inhibition of P. falciparum growth (IC50 <500 nM) and good selectivity for P. falciparum versus human neonatal foreskin fibroblast cells (selectivity index >100). Two of these compounds, 8 and 33, exhibited good aqueous solubility and metabolic stability, and when administered subcutaneously to mice (32 mg kg(-1)), plasma concentrations remained above 0.2 µM for at least 8 h. Both 8 and 33 were well tolerated in mice after subcutaneous administration of 32 mg kg(-1) twice daily for 4 days. Using this regimen blood stage P. berghei was suppressed by 52% for 8 and 26% for 33, relative to the vehicle control.


Subject(s)
Amides/chemistry , Antimalarials/chemistry , Antimalarials/pharmacology , Biological Products/chemistry , Triazines/chemistry , Triazines/pharmacology , Urea/chemistry , Animals , Antimalarials/adverse effects , Antimalarials/pharmacokinetics , Atovaquone/pharmacology , Cell Line , Chemistry Techniques, Synthetic , Drug Resistance/drug effects , Female , Humans , Inhibitory Concentration 50 , Malaria/drug therapy , Male , Mice , Plasmodium berghei/drug effects , Plasmodium berghei/physiology , Plasmodium falciparum/drug effects , Structure-Activity Relationship , Triazines/adverse effects , Triazines/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL